IVV法
Single Cell Transcriptome解析
成果
GVHD：
- Shono, Y. et al., Blood, 115: 5401-5411 (2010).
Link: https://www.ncbi.nlm.nih.gov/pubmed/20354171 - Ueha, S. et al., Cancer Sci., 108: 1967-1973 (2017).
Link: https://www.ncbi.nlm.nih.gov/pubmed/28787768 - Ni, X. et al., J. Clin. Invest., 127: 1960-1977 (2017).
Link: https://www.ncbi.nlm.nih.gov/pubmed/28414296
Solid Tumors：
- Ueha, S. et al., Cancer Immunol. Res., 3: 631-640 (2015).
Link: https://www.ncbi.nlm.nih.gov/pubmed/25711759 - Cancer biology and new seeds
ヒト型化抗CD4抗体のがん治療薬としての開発研究
Development of a humanized anti-CD4 antibody as a cancer therapeutic
がん分子標的治療 Vol.13 No.2, 99-104, 2015
松島綱治 ／ 上羽悟史 ／ 垣見和宏
| 学会・研究会名 | 発表日時 | 表題 | 発表者 |
|---|---|---|---|
| 第73回日本癌学会学術総会 | 27-Sep-14 | マウス固形がんモデルにおける、免疫チェックポイント抗体との併用による、抗CD4抗体の相乗的抗腫瘍効果 Synergistic anti-tumor effect of CD4 depleting antibody with immune checkpoi nt antibodies in murine tumor models |
Ueha1, Satoshi1. Shoji Yokochi1,2, Yoshiro Ishiwata1,2, Satoru Ito1,2, Yuya Terashima1, Kazuhiro Kakimi3, Matsushima1 1) The Department of Molecular Preventive Medicine, The University of Tokyo, 2) IDAC Theranostics, Inc. 3) The Department of Immunotherapeutics, The University of Tokyo Hospital |
| 第43回日本免疫学会学術総会 | 10-Dec-14 | Administration of anti-CD4 depleting antibody together with anti-PD-1/anti-PD-L1 antibody shows dramatic anti-tumor effects in mice | Y. Ishiwata1,2, S. Yokochi2, K. Kakimi3, S. Ueha1, S. Ito2, K. Matsushima1 1) The Department of Molecular Preventive Medicine, The University of Tokyo, 2) IDAC Theranostics, Inc. 3) The Department of Immunotherapeutics, The University of Tokyo Hospital |
| 第43回日本免疫学会学術総会 | 10-Dec-14 | Loss of Lympho node fibroblastic reticular cells and high endothelial cells underlies humoral Immunomodeficiency in mouse GVHD | Ueha1, Satoshi1. Shoji Yokochi1,2, Yoshiro Ishiwata1,2, Satoru Ito1,2, Yuya Terashima1, Kazuhiro Kakimi3, Matsushima1 1) The Department of Molecular Preventive Medicine, The University of Tokyo, 2) IDAC Theranostics, Inc. 3) The Department of Immunotherapeutics, The University of Tokyo Hospital |
| The AACR Annual Meeting | 19-Apr-15 | Robust anti-tumor effects of combined anti-CD4 depleting antibody and anti-PD-1/PD-L1 immune checkpoint antibody treatment in mice | Satoru Ito1,2, Satoshi Ueha1, Shoji Yokochi1,2, Yoshiro Ishiwata1,2, Kosuke Hachiga1,2, Haru Ogiwara1, Krishant Chand1 , Takumi Nakajima1, Kazuhiro Kakimi3, Kouji Matsushima1 Dep. of Molecular Preventive Medicine, Graduate School of Medicine, The Univ. of Tokyo; 2:IDAC Theranostics, Inc. , 3:Dep. of Immunotherapeutics, The Univ. of Tokyo Hospital |
| がん免疫療法・マクロファージ国際会議2015（ICCIM2015） （第19回日本がん免疫学会＋第23回マクロファージ分子細胞生物学国際シンポジウム） |
9-Jul-15 | Amelioration of GVHD maintaining GVT effect on allo-HSCT by depletion of donor CD4+ T cells in solid-tumor bearing mouse model | Ueha1, Satoshi1. Shoji Yokochi1,2, Yoshiro Ishiwata1,2, Satoru Ito1,2, Yuya Terashima1, Kazuhiro Kakimi3, Matsushima1 1) The Department of Molecular Preventive Medicine, The University of Tokyo, 2) IDAC Theranostics, Inc. 3) The Department of Immunotherapeutics, The University of Tokyo Hospital |
| 第74回日本癌学会学術総会 | 10-Oct-15 | 抗CD4抗体による4T1マウス乳がん自然転移の抑制 Suppression of tumor metastasis in 4T1 breast cancer model with anti-CD4 monoclonal antibody treatment |
Shoji Yokochi1, Satoshi Ueha2, Yoshiro Ishiwata1, Satoru Ito1, Kouji Matsushima2 1 IDAC Theranostics, Inc., Tokyo, Japan; 2 The University of Tokyo, Tokyo, Japan |
| 第74回日本癌学会学術総会 | 10-Oct-15 | 抗CD4除去抗体と抗PD-L1免疫チェックポイント抗体の併用量による抗腫瘍作用 Robust anti-tumor effects of combined anti-CD4 depleting antibody and snti-PD-L1 antibody treatment in mice |
Ueha1, Satoshi1. Shoji Yokochi1,2, Yoshiro Ishiwata1,2, Satoru Ito1,2, Yuya Terashima1, Kazuhiro Kakimi3, Matsushima1 1) The Department of Molecular Preventive Medicine, The University of Tokyo, 2) IDAC Theranostics, Inc. 3) The Department of Immunotherapeutics, The University of Tokyo Hospital |
| 第44回日本免疫学会学術総会 | 19-Nov-15 | Anti-CD4 depleting mAb administration improves costimulatory signals and cytokine microenvironments in the tumor draining lympho node | Ueha1, Satoshi1. Shoji Yokochi1,2, Yoshiro Ishiwata1,2, Satoru Ito1,2, Yuya Terashima1, Kazuhiro Kakimi3, Matsushima1 1) The Department of Molecular Preventive Medicine, The University of Tokyo, 2) IDAC Theranostics, Inc. 3) The Department of Immunotherapeutics, The University of Tokyo Hospital |
| American Association for Cancer Reseach | 発表2016.4.17 | An anti-CD4 antibody protects mice from anti-PD-1/PD-L1 antibody-induced fatal anaphylaxis and shows potent anti-metastatic activity in the 4T1 spontaneous metastasis model | Satoru Ito1,2, Shoji Yokochi1,2, Yoshiro Ishiwata1,2, Satoshi Ueha1, Francis Shand1, Kouji Matsushima1 Dep. of Molecular Preventive Medicine, Graduate School of Medicine, The Univ. of Tokyo; 2:IDAC Theranostics, Inc. |